INTELLIGENT BIO SOLUTIONS INC. (INBS) Free cash flow
- Free cash flow · 12 months (USD): Value $-12.05M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -285.94%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-12.05M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-11.93M − $125.73K ≈ $-12.05M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -285.94% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-12.05M ÷ $4.22M × 100 ≈ -285.94% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-11.93M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.96× | Operating cash flow / net income. Period ending 2026-06-30. $-11.93M ÷ $-12.43M ≈ 0.96× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -11.93M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 125.73K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -12.05M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 4.22M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -12.43M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-12.05M | (m) | $-11.93M | $125.73K | (m) | $4.22M | (m) | $-12.43M | (m) | (m) | -285.94% | 0.96× |
| 2026-03-31 | (m) | (m) | $-10.95M | (m) | (m) | $3.91M | (m) | $-11.61M | (m) | (m) | (m) | 0.94× |
| 2025-12-31 | $-9.74M | (m) | $-9.38M | $361.54K | (m) | $3.58M | (m) | $-11.29M | (m) | (m) | -272.00% | 0.83× |
| 2025-09-30 | (m) | (m) | $-10.14M | (m) | (m) | $3.29M | (m) | $-10.87M | (m) | (m) | (m) | 0.93× |
| 2025-06-30 | $-9.91M | (m) | $-9.68M | $231.84K | (m) | $3.05M | (m) | $-10.57M | (m) | (m) | -324.62% | 0.92× |
| 2025-03-31 | (m) | (m) | $-10.41M | (m) | (m) | $2.94M | (m) | $-10.26M | (m) | (m) | (m) | 1.01× |
| 2024-12-31 | (m) | (m) | $-10.10M | (m) | (m) | $3.03M | (m) | $-10.70M | (m) | (m) | (m) | 0.94× |
| 2024-09-30 | (m) | (m) | $-10.65M | (m) | (m) | $3.19M | (m) | $-10.42M | (m) | (m) | (m) | 1.02× |
| 2024-06-30 | $-9.58M | (m) | $-9.57M | $5.37K | (m) | $3.11M | (m) | $-10.16M | (m) | (m) | -307.76% | 0.94× |
| 2024-03-31 | (m) | (m) | $-7.21M | (m) | (m) | $2.83M | (m) | $-10.03M | (m) | (m) | (m) | 0.72× |
| 2023-12-31 | (m) | (m) | $-7.28M | (m) | (m) | $2.46M | (m) | $-13.40M | (m) | (m) | (m) | 0.54× |
| 2023-09-30 | (m) | (m) | $-6.80M | (m) | (m) | $1.74M | (m) | $-11.85M | (m) | (m) | (m) | 0.57× |
| 2023-06-30 | (m) | (m) | $-7.38M | (m) | (m) | $1.26M | (m) | $-10.63M | (m) | (m) | (m) | 0.69× |
| 2023-03-31 | (m) | (m) | $-8.52M | (m) | (m) | $880.59K | (m) | $-10.05M | (m) | (m) | (m) | 0.85× |
| 2022-12-31 | (m) | (m) | $-6.29M | (m) | (m) | $616.03K | (m) | $-5.04M | (m) | (m) | (m) | 1.25× |
| 2022-09-30 | (m) | (m) | $-5.33M | (m) | (m) | $748.47K | (m) | $-8.08M | (m) | (m) | (m) | 0.66× |
| 2022-06-30 | (m) | (m) | $-3.36M | (m) | (m) | $437.15K | (m) | $-8.31M | (m) | (m) | (m) | 0.40× |
| 2022-03-31 | (m) | (m) | $-3.32M | (m) | (m) | $1.98M | (m) | $-7.08M | (m) | (m) | (m) | 0.47× |
| 2021-12-31 | (m) | (m) | $-9.18M | (m) | (m) | $1.82M | (m) | $-8.87M | (m) | (m) | (m) | 1.04× |
| 2021-09-30 | (m) | (m) | $-8.54M | (m) | (m) | (m) | (m) | $-7.40M | (m) | (m) | (m) | 1.15× |
| 2021-06-30 | (m) | (m) | $-11.30M | (m) | (m) | $1.98M | (m) | $-7.04M | (m) | (m) | (m) | 1.61× |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-4.86M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $-498.62K | (m) | (m) | $188.74K | (m) | $-3.16M | (m) | (m) | (m) | 0.16× |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |